Zobrazeno 1 - 10
of 66
pro vyhledávání: '"Martina Maurelli"'
Autor:
Mario Valenti, Luigi Gargiulo, Luciano Ibba, Piergiorgio Malagoli, Fabrizio Amoruso, Anna Balato, Federico Bardazzi, Martina Burlando, Carlo G. Carrera, Paolo Dapavo, Valentina Dini, Francesca M. Gaiani, Giampiero Girolomoni, Claudio Guarneri, Claudia Lasagni, Francesco Loconsole, Angelo V. Marzano, Martina Maurelli, Matteo Megna, Diego Orsini, Massimo Travaglini, Antonio Costanzo, Alessandra Narcisi
Publikováno v:
Dermatology and Therapy, Vol 14, Iss 6, Pp 1649-1657 (2024)
Abstract Introduction The introduction of biological therapies has revolutionized the treatment of moderate-to-severe plaque psoriasis. In particular, ixekizumab, an inhibitor of interleukin-17A, has shown great results in terms of efficacy and safet
Externí odkaz:
https://doaj.org/article/2457ce851f3b4d589b890cf51ca53d3c
Autor:
Luigi Gargiulo, Luciano Ibba, Angela Alfano, Piergiorgio Malagoli, Fabrizio Amoruso, Anna Balato, Francesca Barei, Anna G. Burroni, Stefano Caccavale, Piergiacomo Calzavara-Pinton, Maria Esposito, Maria C. Fargnoli, Silvia M. Ferrucci, Caterina Foti, Giampiero Girolomoni, Massimo Gola, Mario B. Guanti, Carlotta Gurioli, Manfredi Magliulo, Martina Maurelli, Pietro Morrone, Maria L. Musumeci, Maddalena Napolitano, Michela Ortoncelli, Cataldo Patruno, Bianca M. Piraccini, Elena Pezzolo, Simone Ribero, Mariateresa Rossi, Paola Savoia, Claudio Sciarrone, Benedetta Tirone, Marco Vaccino, Federica Veronese, Antonio Costanzo, Alessandra Narcisi
Publikováno v:
Journal of Dermatological Treatment, Vol 35, Iss 1 (2024)
Aim: Abrocitinib is a JAK-1 inhibitor approved for the treatment of moderate-to-severe atopic dermatitis (AD). We conducted a 16-week multicenter retrospective study to assess the short-term effectiveness and safety of abrocitinib in patients with mo
Externí odkaz:
https://doaj.org/article/480e38bfd8864c22af37d930c2f6d234
Autor:
Diego Orsini, Piergiorgio Malagoli, Anna Balato, Luca Bianchi, Pina Brianti, Dario Buononato, Martina Burlando, Giacomo Caldarola, Anna Campanati, Elena Campione, Carlo G. Carrera, Andrea Carugno, Francesco Cusano, Paolo Dapavo, Annunziata Dattola, Clara De Simone, Valentina Dini, Maria Esposito, Maria C. Fargnoli, Francesca M. Gaiani, Luigi Gargiulo, Paolo Gisondi, Alessandro Giunta, Luciano Ibba, Claudia Lasagni, Francesco Loconsole, Vincenzo Maione, Edoardo Mortato, Angelo V. Marzano, Martina Maurelli, Matteo Megna, Santo R. Mercuri, Alessandra Narcisi, Annamaria Offidani, Giovanni Paolino, Aurora Parodi, Giovanni Pellacani, Luca Potestio, Pietro Quaglino, Antonio G. Richetta, Francesca Romano, Paolo Sena, Marina Venturini, Chiara Assorgi, Antonio Costanzo
Publikováno v:
Dermatology Practical & Conceptual, Vol 14, Iss 2 (2024)
Introduction: Genital involvement is observed in approximately 60% of patients with psoriasis, presenting clinicians with formidable challenges in treatment. While new biologic drugs have emerged as safe and effective options for managing psoriasis,
Externí odkaz:
https://doaj.org/article/59fd209fd8eb441cabd179657001da3a
Publikováno v:
Acta Dermato-Venereologica, Vol 103 (2023)
Atopic dermatitis is a common inflammatory disease with a chronic and relapsing course. Although considered a childhood disease, it is now evident that atopic dermatitis is also common in adulthood and in the elderly population. Atopic dermatitis typ
Externí odkaz:
https://doaj.org/article/c414007e39f64b32a96068dfbf76d3a3
Publikováno v:
Journal of Dermatological Treatment, Vol 34, Iss 1 (2023)
Background Pharmacoeconomic studies examining the cost-effectiveness of adalimumab biosimilars versus methotrexate in real-life settings are limited. Objectives To assess the cost per responder from the perspective of the National Health System of ad
Externí odkaz:
https://doaj.org/article/1a30bb46a44849e1839c9941902c4414
Autor:
Andrea Chiricozzi, Giacomo Dal Bello, Niccolò Gori, Lucia Di Nardo, Donatella Schena, Giacomo Caldarola, Martina Maurelli, Clara De Simone, Giampiero Girolomoni, Ketty Peris
Publikováno v:
Journal of Dermatological Treatment, Vol 34, Iss 1 (2023)
Background Dupilumab is a monoclonal antibody against the IL-4/IL-13 receptor-subunit approved for the treatment of moderate-severe atopic dermatitis (AD). Some attempts to increase dose interval have been described in both trial and real-world setti
Externí odkaz:
https://doaj.org/article/3f1d6455feae44de9dc4877e6bacd356
Autor:
Luigi Gargiulo, Alessandra Narcisi, Luciano Ibba, Anna Balato, Luca Bianchi, Pina Brianti, Dario Buononato, Martina Burlando, Giacomo Caldarola, Anna Campanati, Elena Campione, Carlo G. Carrera, Andrea Carugno, Antonio Cristaudo, Francesco Cusano, Paolo Dapavo, Annunziata Dattola, Clara De Simone, Francesca M. Gaiani, Paolo Gisondi, Alessandro Giunta, Francesco Loconsole, Vincenzo Maione, Edoardo Mortato, Angelo V. Marzano, Martina Maurelli, Matteo Megna, Santo R. Mercuri, Annamaria Offidani, Diego Orsini, Aurora Parodi, Giovanni Pellacani, Luca Potestio, Pietro Quaglino, Antonio G. Richetta, Francesca Romano, Paolo Sena, Marina Venturini, Piergiorgio Malagoli, Antonio Costanzo
Publikováno v:
Frontiers in Medicine, Vol 10 (2023)
IntroductionBimekizumab is a monoclonal antibody that targets Interleukin-17 A and F, approved for the treatment of moderate-to-severe plaque psoriasis. While bimekizumab has been evaluated in several phase-III clinical trials, real-world evidence is
Externí odkaz:
https://doaj.org/article/a57a586330ad40f1847d355dbee4ceef
Publikováno v:
JEADV Clinical Practice, Vol 1, Iss 3, Pp 281-283 (2022)
Externí odkaz:
https://doaj.org/article/cd600ed4542745d2957940425e56d80a
Publikováno v:
Case Reports in Dermatology, Vol 13, Iss 2, Pp 282-288 (2021)
Annually recurring erythema annulare centrifugum (AR-EAC) is a rare variant, characterized by typical annular plaques recurring in the same period of the year. We describe 5 new cases and present a review of the literature. Patients were 3 females an
Externí odkaz:
https://doaj.org/article/b21c66460c9a4b6da66b6ac21b1107d7
Publikováno v:
Vaccines, Vol 11, Iss 3, p 617 (2023)
Advanced glycation end products (AGEs) are biologically active compounds formed physiologically throughout a sequence of chemical reactions, to generate highly oxidant-reactive aldehydes that combine covalently to proteins. They accumulate slowly in
Externí odkaz:
https://doaj.org/article/5f1498ce98bf436ca62b8c2a27913f62